Pfizer reports FY2025 revenue $62.6B, adj. EPS $3.22; reaffirms FY2026 guidance

PFIZER INC

2025-FY EPS reported $1.36 revenue$62,579,000,000

Full-year 2025 revenue $62.6B (-2% operational); non-COVID portfolio +6% operational.
FY2025 reported diluted EPS $1.36; adjusted diluted EPS $3.22 (+4% YoY).
Q4 2025 revenue $17.6B (-1%); Q4 reported LPS ($0.29); adj. diluted EPS $0.66.
Completed Metsera acquisition (~$7B); ViiV stake sale for $1.875B; reaffirms FY2026 revenue guidance $59.5-62.5B, adj. EPS $2.80-3.00.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.